oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 41 )

2018 ( 157 )

2017 ( 182 )

2016 ( 188 )

Custom range...

Search Results: 1 - 10 of 23706 matches for " Ji-Eun Park "
All listed articles are free for downloading (OA Articles)
Page 1 /23706
Display every page Item
Isolation of aromatic yeasts(non-Saccharomyces cerevisiae) from Korean traditional nuruks and identification of fermentation characteristics  [PDF]
Choi Ji Ho, Soo Hwan Yeo, Ji-Hye Park, Han Seok Choi, Ji-Eun Gang, Soo In Kim, Seok Tae Jeong, So Ra Kim
Agricultural Sciences (AS) , 2013, DOI: 10.4236/as.2013.45B025
Abstract:

Ethyl caproate and isoamyl alcohol are important for the quality of Yakju, one of the Korean traditional alcoholic beverages. From Korean traditional fermentation agent, Nuruk, we have isolated 8 yeasts which produced rich aromatic compounds using YEPD agar plates (1% yeast extract, 2% peptone, 2% dextrose, 2% agar) containing 50 uL cerulenin at 30℃. The isolated aromatic yeasts are identified as Pichia anomala (4 strains), Pichia fabianii (2 strains), Pichia farinose (1 strains), Geotrichum candidum (1 strains). We conducted alcohol fermentation with each of the aromatic yeasts and the compounds (ethyl caproate and isoamyl alcohol) producing range were 59.5 - 193.2 ppm and 10.8 - 91.6 ppm respectively. As a control, Fermivin®, famous aromatic wine yeast, was 89.4 ppm and 16.2 ppm respectively. We also find that the isolated Pichia anomala could produce higher level ethanol (4.2% - 5.0%, v/v) than other species (0.4% - 2.2%, v/v). Using the aromatic yeasts in fermentation industries, we expect to improve the quality of traditional alcoholic beverages.

Effects of moxibustion for constipation treatment: a systematic review of randomized controlled trials
Myeong Soo Lee, Tae-Young Choi, Ji-Eun Park, Edzard Ernst
Chinese Medicine , 2010, DOI: 10.1186/1749-8546-5-28
Abstract: Chronic constipation is a prevalent health condition with patients typically having bowel movements twice a week or less for at least two consecutive weeks or longer. The Rome II criteria define chronic constipation on the basis of two or more of the following symptoms at least 25% of the time for at least 12 weeks in the preceding year: straining at defection, lumpy/hard stools, sensations of incomplete evacuation and three or fewer bowel movements per week [1]. Currently, there is no optimal therapeutic solution for this condition.Acupuncture and moxibustion are increasingly used for the treatment of gastrointestinal (GI) diseases [2-4]. Moxibustion is a Chinese medicine treatment whereby an acupoint is stimulated by the heat generated from burning Artemisia vulgaris [5]. Direct moxibustion is applied to the skin surface, whereas indirect moxibustion is performed with some insulating materials (e.g. ginger, salt) placed between the moxa cone and the skin [5]. The heat is then used to warm the skin at the acupoint.Chinese medicine has a unique approach to diagnosis of constipation [6]. According to Chinese medicine theory, there are four constipation patterns, namely differentiation constipation (including heat constipation), cold constipation, qi constipation and deficiency constipation. The draining method employing filiform needles is used to treat heat constipation and qi constipation [7]. In general, moxibustion is used to treat cold constipation, and deficiency constipation [8].A possible explanation is that the heat stimulates acupoints thereby increasing qi circulation and relieving qi stagnation [9], leading to increased frequency of bowel movement.Among three available systematic reviews on acupuncture for constipation [10-12], two reviews regarded constipation as part of a range of GI disorders [11,12] and included only one uncontrolled observational study. The third systematic review focused on auriculotherapy [10] and included only non-randomized clini
2,9,16,19,22,25-Hexaoxatetracyclo[24.4.0.24,7.010,15]dotriaconta-1(26),4,6,10(15),11,13,27,29,31-nonaene
Jai Young Lee,Ji-Eun Lee,Wonbo Sim,Ki-Min Park
Acta Crystallographica Section E , 2009, DOI: 10.1107/s1600536809035399
Abstract: The title 22-crown-6 unit, C26H28O6, comprising of three benzo groups and triethylene glycol, was prepared by the reaction of α,α′-dibromo-p-xylene with 1,8-bis(2-hydroxyphenoxy)-3,6-dioxaoctane in the presence of Cs2CO3 with tetrahydrofuran (THF) and recrystallized from dichloromethane–hexane (1:20 v/v) at room temperature. In the molecular structure, two O atoms of the central ethylene glycol in the triethylene glycol unit exhibit exo conformations due to intramolecular C—H...O interactions. A number of C—H...O and C—H...π intermolecular interactions contribute to the stabilization of the crystal packing.
Efficacy of moxibustion for pre- or stage I hypertension: study protocol for a pilot randomized controlled trial
Shin Kyung-Min,Park Ji-Eun,Liu Yan,Jung Hee-Jung
Trials , 2012, DOI: 10.1186/1745-6215-13-188
Abstract: Background Hypertension is a risk factor for cardiovascular disease, and the prevalence of hypertension tends to increase with age. Current treatments for hypertension have adverse side effects and poor adherence. The purpose of this study is to evaluate the effects of moxibustion on blood pressure in individuals with pre- or stage I hypertension. Methods/design Forty-five subjects with pre- or stage I hypertension will be randomized into three groups: treatment group A (2 times/week), treatment group B (3 times/week), and the control group (non-treated group). The inclusion criteria will be as follows: (1) aged between 19 and 65 years; (2) prehypertension or stage I hypertension (JNC 7, Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure); (3) the participants are volunteers and written consent obtained. The participants in the treatment group A will undergo indirect moxibustion 2 times per week for 4 weeks, and the participants in the treatment group B will undergo indirect moxibustion 3 times per week for 4 weeks. The participants in the control group (non-treated group) will maintain their current lifestyle, including diet and exercise. The use of antihypertensive medication is not permitted. The primary endpoint will be a change in patient blood pressure. The secondary endpoints will be the body mass index, lipid profile, EuroQol and Heart Rate Variability. The data will be analyzed with the Student’s t-test and analysis of variance (ANOVA) (p < 0.05). Discussion The results of this study will help to establish the optimal approach for the care of adults with pre- or stage I hypertension. Trial registration Clinical Research Information Service KCT0000469
Moxibustion for cancer care: a systematic review and meta-analysis
Myeong Soo Lee, Tae-Young Choi, Ji-Eun Park, Song-Shil Lee, Edzard Ernst
BMC Cancer , 2010, DOI: 10.1186/1471-2407-10-130
Abstract: We searched the literature using 11 databases from their inceptions to February 2010, without language restrictions. We included randomised clinical trials (RCTs) in which moxibustion was employed as an adjuvant treatment for conventional medicine in patients with any type of cancer. The selection of studies, data extraction, and validations were performed independently by two reviewers.Five RCTs compared the effects of moxibustion with conventional therapy. Four RCTs failed to show favourable effects of moxibustion for response rate compared with chemotherapy (n = 229, RR, 1.04, 95% CI 0.94 to 1.15, P = 0.43). Two RCTs assessed the occurrence of side effects of chemotherapy and showed favourable effects of moxibustion. A meta-analysis showed significant less frequency of nausea and vomiting from chemotherapy for moxibustion group (n = 80, RR, 0.38, 95% CIs 0.22 to 0.65, P = 0.0005, heterogeneity: χ2 = 0.18, P = 0.67, I2 = 0%).The evidence is limited to suggest moxibustion is an effective supportive cancer care in nausea and vomiting. However, all studies have a high risk of bias so effectively there is not enough evidence to draw any conclusion. Further research is required to investigate whether there are specific benefits of moxibustion for supportive cancer care.Most cancer patients experience multiple symptoms related to either the cancer itself or late treatment effects [1]. The frequently experienced and severe adverse events associated with such treatments lead patients to seek supportive complementary and alternative medicine (CAM) [2]. Most patients use CAM as an adjunct to conventional treatments [3-5]. Acupuncture type interventions are one of the most popular forms of CAM [6]. It is now a widely accepted intervention for the treatment of a variety of conditions [7]. Several reviews claim that acupuncture offers therapeutic benefits for cancer patients [8-10]. Moxibustion is a traditional Chinese method that uses the heat generated by burning herbal prep
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions
Andrea L Ciaranello, Ji-Eun Park, Lynn Ramirez-Avila, Kenneth A Freedberg, Rochelle P Walensky, Valeriane Leroy
BMC Medicine , 2011, DOI: 10.1186/1741-7015-9-59
Abstract: Mother-to-child transmission (MTCT) of HIV-1 results in approximately 370,000 infant infections worldwide each year [1]. HIV-1 early infant diagnosis (EID) programs seek to inform the caregivers of HIV-exposed infants of infant HIV infection status, and to link HIV-infected infants to care and treatment. EID of HIV confers substantial benefits to infants and families, both for HIV-infected and uninfected infants, as well as to programs providing prevention of mother-to-child transmission (PMTCT) services. The World Health Organization (WHO) estimates that only 6% to 15% of HIV-exposed infants under 1 year of age accessed EID programs in 2008-2009 [2], highlighting that the implementation of effective EID programs has been challenging in resource-limited settings and demands careful attention.A frequently cited barrier to expansion of EID programs is the availability and cost of the required laboratory assays, which are usually PCR based and therefore more expensive than the antibody-based testing used for older children and adults [3,4]. However, cost is not the only barrier to implementing EID programs. Opportunities to optimize infant outcomes may be lost at each step in a 'cascade' of EID and pediatric HIV care (Figure 1), conceptually similar to the recently described 'cascade' of care required for effective PMTCT services [5]. The EID cascade includes the offer and acceptance of EID testing among HIV-exposed infants, including those for whom HIV exposure was unknown; accurate specimen collection, transport, and laboratory processing; relay of results to both healthcare providers and infants' families/caregivers; and linkage to care, cotrimoxazole prophylaxis, and antiretroviral therapy (ART) for infants identified as HIV infected. In this review, we outline the ways in which interventions targeting each step in this EID cascade may impact clinical outcomes, costs, and cost effectiveness of EID programs.In adults and older children, chronic HIV-1 infection can b
Evaluation of Protective Efficacy of Respiratory Syncytial Virus Vaccine against A and B Subgroup Human Isolates in Korea
Ji-Eun Jang, Jee-Boong Lee, Kyung-Hyo Kim, Sung Moo Park, Byoung-Shik Shim, In Soo Cheon, Man Ki Song, Jun Chang
PLOS ONE , 2011, DOI: 10.1371/journal.pone.0023797
Abstract: Human respiratory syncytial virus (HRSV) is a significant cause of upper and lower respiratory tract illness mainly in infants and young children worldwide. HRSV is divided into two subgroups, HRSV-A and HRSV-B, based on sequence variation within the G gene. Despite its importance as a respiratory pathogen, there is currently no safe and effective vaccine for HRSV. In this study, we have detected and identified the HRSV by RT-PCR from nasopharyngeal aspirates of Korean pediatric patients. Interestingly, all HRSV-B isolates exhibited unique deletion of 6 nucleotides and duplication of 60 nucleotides in the G gene. We successfully amplified two isolates (‘KR/A/09-8’ belonging to HRSV-A and ‘KR/B/10-12’ to HRSV-B) on large-scale, and evaluated the cross-protective efficacy of our recombinant adenovirus-based HRSV vaccine candidate, rAd/3xG, by challenging the immunized mice with these isolates. The single intranasal immunization with rAd/3xG protected the mice completely from KR/A/09-8 infection and partially from KR/B/10-12 infection. Our study contributes to the understanding of the genetic characteristics and distribution of subgroups in the seasonal HRSV epidemics in Korea and, for the first time, to the evaluation of the cross-protective efficacy of RSV vaccine against HRSV-A and -B field-isolates.
PDHK-2 Deficiency Is Associated with Attenuation of Lipase-Mediated Fat Consumption for the Increased Survival of Caenorhabditis elegans Dauers
Sunhee Kim, E-Jin Shin, Jeong-Hoon Hahm, Pil-Jong Park, Ji-Eun Hwang, Young-Ki Paik
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0041755
Abstract: In Caenorhabditis elegans, slow fat consumption has been suggested to contribute to the extension of the survival rate during nutritionally adverse conditions. Here, we investigated the potential role of pyruvate dehydrogenase kinase (PDHK)-2, the C. elegans homolog of mammalian PDK, effects on fat metabolism under nutritional conditions. PDHK-2 was expressed at low levels under well-fed conditions but was highly induced during long-term starvation and in the dauer state. This increase in pdhk-2 expression was regulated by both DAF-16 and NHR-49. Dauer-specific induction of PDHK-2 was abolished upon entry into the post-dauer stage. Interestingly, in the long-term dauer state, stored fat levels were higher in daf-2(e1370);pdhk-2 double mutants than in daf-2(e1370), suggesting a positive relationship between PDHK-2 activity and fat consumption. PDHK-2 deficiency has been shown to lead to greater preservation of residual fats, which would be predicted to contribute to survival during the dauer state. A test of this prediction showed that the survival rates of daf-2(e1370);pdhk-2(tm3075) and daf-2(e1370);pdhk-2(tm3086) double mutants were higher than that of daf-2(e1370), suggesting that loss of either the ATP-binding domain (tm3075) or branched chain keto-acid dehydrogenase kinase domain (tm3086) of PDHK-2 leads to reduced fat consumption and thus favors increased dauer survival. This attenuated fat consumption in the long-term dauer state of C. elegans daf-2 (e1370);pdhk-2 mutants was associated with concomitant down-regulation of the lipases ATGL (adipose triglyceride lipase), HSL (hormone-sensitive lipase), and C07E3.9 (phospholipase). In contrast, PDHK-2 overexpression in wild-type starved worms induced lipase expression and promoted abnormal dauer formation. Thus, we propose that PDHK-2 serves as a molecular bridge, connecting fat metabolism and survival under nutritionally adverse conditions in C. elegans.
The effectiveness of moxibustion for the treatment of functional constipation: a randomized, sham-controlled, patient blinded, pilot clinical trial
Ji-Eun Park, Jae-Uk Sul, Kyungwon Kang, Byung-Cheul Shin, Kwon-Eui Hong, Sun-Mi Choi
BMC Complementary and Alternative Medicine , 2011, DOI: 10.1186/1472-6882-11-124
Abstract: Twenty-six participants (identified with either qi (vital energy) deficiency or qi excess syndrome) were randomly divided into either a moxibustion or sham group. Participants were treated with real or sham moxibustion at 4 acupuncture points, ST23 and ST27, bilaterally, 3 times per week for four weeks. The primary outcome was the frequency of defecations; secondary outcomes were the Bristol stool form scale (BSS) and the constipation assessment scale (CAS).Of the 26 participants that were randomized, 24 completed the study. Defecation frequency, BSS, and CAS showed no difference between the moxibustion and sham groups. The differences were -0.25 (95% CI: -2.08, 1.58, p = 0.78), -1.22 (95% CI: -2.7, 0.26, p = 0.1), 0.91 (95% CI: -1.46, 3.28, p = 0.44) in defecation frequency, BSS, CAS, respectively. The defecation frequency increased from an average of 3.3 to 4.6 times per week in the moxibustion group (1.5[-0.5, 2], p = 0.06) and from 2.7 to 3.7 stools per week in the sham group (1[-1, 2], p = 0.15) after four weeks of treatment. The difference between participants with a deficiency or an excess syndrome, determined based on assessment of sweat, facial features, pain, body energy, and pulse type, was significant in only defecation frequency. The difference was 3.3 (95% CI: 0.41, 6.19, p = 0.03).Moxibustion treatment appears safe, but showed no positive effect on constipation. The effectiveness of moxibustion treatment may depend on the syndrome pattern, and further long-term studies with a larger number of subjects are warranted.Clinical Research Information Service, KCT0000168Constipation is a common gastrointestinal complaint that is experienced by 27.2% of Canadians [1], 12%-19% of Americans [2], and 14% of Asians [3], with a prevalence of 11.6% in the elderly Asian [4]. In Korea, the prevalence is 16.5% for self-reported constipation, 9.2% for functional constipation and 3.9% for constipation-predominant irritable bowel syndrome [5].Constipation can cause abdom
Does Glycine max leaves or Garcinia Cambogia promote weight-loss or lower plasma cholesterol in overweight individuals: a randomized control trial
Ji-Eun Kim, Seon-Min Jeon, Ki Park, Woo Lee, Tae-Sook Jeong, Robin A McGregor, Myung-Sook Choi
Nutrition Journal , 2011, DOI: 10.1186/1475-2891-10-94
Abstract: Eighty-six overweight subjects (Male:Female = 46:40, age: 20~50 yr, BMI > 23 < 29) were randomly assigned to three groups and administered tablets containing EGML (2 g/day), GCE (2 g/day) or placebo (starch, 2 g/day) for 10 weeks. At baseline and after 10 weeks, body composition, plasma cholesterol and diet were assessed. Blood analysis was also conducted to examine plasma lipoproteins, triglycerides, adipocytokines and antioxidants.EGML and GCE supplementation failed to promote weight-loss or any clinically significant change in %body fat. The EGML group had lower total cholesterol after 10 weeks compared to the placebo group (p < 0.05). EGML and GCE had no effect on triglycerides, non-HDL-C, adipocytokines or antioxidants when compared to placebo supplementation. However, HDL-C was higher in the EGML group (p < 0.001) after 10 weeks compared to the placebo group.Ten weeks of EGML or GCE supplementation did not promote weight-loss or lower total cholesterol in overweight individuals consuming their habitual diet. Although, EGML did increase plasma HDL-C levels which is associated with a lower risk of atherosclerosis.Obesity is a major threat to worldwide public health and is recognized as a major factor contributing to insulin resistance, type 2 diabetes, hyperlipidemia, hypertension, cardiovascular disease and all-cause mortality [1,2]. A modest weight loss in obese or overweight individuals is reported to be associated with decreased risk of co-morbidities and mortality [3]. Furthermore, reduction in total cholesterol or low-density lipoprotein cholesterol (LDL-C) through diet therapy or drug administration has been shown to decrease the risk of cardiovascular disease [4].Natural food supplements are widely used by individuals for potential health benefits such as weight-loss [5,6] and lower cholesterol [7-10]. However, the evidence for the effectiveness of natural food supplements to promote weight-loss and improve health is largely derived from animal studies [
Page 1 /23706
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.